Eton Pharmaceuticals Inc. (ETON) is carving out a strong position in rare disease care, building a fast-growing portfolio of treatments backed by a consistent track record of successful commercialization.
The company has 10 commercial products - INCRELEX for Severe Primary Insulin-Like Growth Factor 1 Deficiency; ALKINDI SPRINKLE for Pediatric Adrenal Insufficiency; KHINDIVI for Pediatric Adrenal Insufficiency; GALZIN for Wilson disease; PKU GOLIKE for Phenylketonuria; Carglumic Acid for Hyperammonemia; Betaine Anhydrous for Homocystinuria; DESMODA for Diabetes Insipidus; HEMANGEOL for Infantile Hemangioma; and Nitisinone for Hereditary Tyrosinemia Type 1 (HT-1).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com